Adaptive Biotechnologies Corporation (ADPT) - Stock Analysis
Last updated: Sep 19, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
ADPT rose 11.6% over 21 sessions and 17.4% in the latest five, closing near its recent high. Updated NCCN guidance specifically supports routine use of Adaptive's FDA-cleared clonoSEQ assay, while MRD revenue growth of 52% and raised growth guidance strengthen the commercial catalyst.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Rising Leverage ⢠Persistent Losses ADPT has strong liquidity but worsening leverage, persistent losses, debt-funded cash growth, and elevated valuation multiples warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Strong upward breakout ⢠Overbought momentum ⢠Pullback risk Support Level: $26.68; stronger support $24.20â$24.80 Resistance Level: $28.61 ADPT is in a strong uptrend above $26.68 support, but its rapid climb to $28.61 and overbought momentum raise near-term pullback risk.
Sentiment & News
Key News Insights: ⢠NCCN guideline support ⢠clonoSEQ recognition ⢠Institutional selling Adaptive Biotechnologies gained clinical momentum as NCCN guidelines endorsed clonoSEQ-based MRD assessment despite Algert Global's major stake reduction.
AI Summary
ADPT's thesis is shifting to whether NCCN-backed clonoSEQ adoption can convert strong test-volume growth into revenue acceleration and operating leverage, but at ~12.7x sales and with rising debt, investors should wait for sustained EBITDA-loss improvement and cash-burn reduction before chasing the momentum-driven breakout.
Description
Adaptive Biotechnologies is a commercial-stage company that develops immune-based diagnostics and therapeutics, offering sequencing and clinical assays to detect and monitor cancer, infectious diseases and immune-related conditions. Its portfolio includes research and clinical immunosequencing products and laboratory diagnostics for minimal residual disease and past infection detection, and it supports life-science research, clinical diagnostics and drug discovery. The company maintains strategic collaborations with Genentech on neoantigen-directed T-cell therapies and with Microsoft on computational diagnostic efforts; it was incorporated in 2009 and is headquartered in Seattle, Washington.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 18 | Sep 25 | ADPT | Adaptive Biotechnologies Corporation | ADPT rose 11.6% over 21 sessions and 17.4% in the latest five, closing near its recent high. Updated NCCN guidance specifically supports routine use of Adaptive's FDA-cleared clonoSEQ assay, while MRD revenue growth of 52% and raised growth guidance strengthen the commercial catalyst. | Closed | +2.9% |
| Nov 25 | Dec 2 | ADPT | Adaptive Biotechnologies Corporation | Adaptive Biotechnologies (ADPT) exhibits strong short-term momentum with a recent earnings beat, 52% YoY MRD revenue growth, raised guidance, and technical breakout above the upper Bollinger Band, complemented by favorable biotech sector tailwinds. | Closed | -8.0% |